% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{vandenBent:283142,
      author       = {M. J. van den Bent and M. Geurts and P. J. French and M.
                      Smits and D. Capper$^*$ and J. E. C. Bromberg and S. M.
                      Chang},
      title        = {{P}rimary brain tumours in adults.},
      journal      = {The lancet},
      volume       = {402},
      number       = {10412},
      issn         = {0140-6736},
      address      = {London [u.a.]},
      publisher    = {Elsevier},
      reportid     = {DKFZ-2023-01929},
      pages        = {1564-1579},
      year         = {2023},
      note         = {2023 Oct 28;402(10412):1564-1579},
      abstract     = {The most frequent adult-type primary CNS tumours are
                      diffuse gliomas, but a large variety of rarer CNS tumour
                      types exists. The classification of these tumours is
                      increasingly based on molecular diagnostics, which is
                      reflected in the extensive molecular foundation of the
                      recent WHO 2021 classification of CNS tumours. Resection as
                      extensive as is safely possible is the cornerstone of
                      treatment in most gliomas, and is now also recommended early
                      in the treatment of patients with radiological evidence of
                      histologically low-grade tumours. For the adult-type diffuse
                      glioma, standard of care is a combination of radiotherapy
                      and chemotherapy. Although treatment with curative intent is
                      not available, combined modality treatment has resulted in
                      long-term survival (>10-20 years) for some patients with
                      isocitrate dehydrogenase (IDH) mutant tumours. Other rarer
                      tumours require tailored approaches, best delivered in
                      specialised centres. Targeted treatments based on molecular
                      alterations still only play a minor role in the treatment
                      landscape of adult-type diffuse glioma, and today are mainly
                      limited to patients with tumours with BRAFV600E (ie,
                      Val600Glu) mutations. Immunotherapy for CNS tumours is still
                      in its infancy, and so far, trials with checkpoint
                      inhibitors and vaccination studies have not shown
                      improvement in patient outcomes in glioblastoma. Current
                      research is focused on improving our understanding of the
                      immunosuppressive tumour environment, the molecular
                      heterogeneity of tumours, and the role of tumour microtube
                      network connections between cells in the tumour
                      microenvironment. These factors all appear to play a role in
                      treatment resistance, and indicate that novel approaches are
                      needed to further improve outcomes of patients with CNS
                      tumours.},
      subtyp        = {Review Article},
      cin          = {BE01},
      ddc          = {610},
      cid          = {I:(DE-He78)BE01-20160331},
      pnm          = {899 - ohne Topic (POF4-899)},
      pid          = {G:(DE-HGF)POF4-899},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:37738997},
      doi          = {10.1016/S0140-6736(23)01054-1},
      url          = {https://inrepo02.dkfz.de/record/283142},
}